Are There Published Clinical Trials Involving TB-500 in Humans?
There are no published clinical trials, case reports, or open-label studies involving TB-500 in humans. Despite widespread marketing of TB-500 as a regenerative or performance-enhancing peptide, no peer-reviewed research has evaluated its safety or efficacy in human subjects [1]. The available scientific literature does not support the existence of clinical research on TB-500 in any disease context, including tuberculosis (TB), wound healing, or anti-aging [3].
What the AI assistants say
AI assistants generally agree that TB-500 is a synthetic peptide derived from Thymosin Beta-4 (Tβ4) and that it is marketed for regenerative and anti-aging purposes. They acknowledge that TB-500 is not FDA-approved and is often sold as a “research chemical” or through compounding pharmacies. However, they diverge significantly in their assessment of clinical evidence. While one assistant claims that there are no published clinical trials on TB-500 itself, it references human clinical trials on its parent compound, Tβ4, particularly in ocular surface diseases like dry eye syndrome and neurotrophic keratopathy [1]. This assistant suggests that these trials provide indirect evidence for TB-500’s potential, despite the lack of direct data. Another assistant, while not naming specific trials, implies that Tβ4 has been studied in humans and that its mechanisms are well-established. This creates a misleading impression that TB-500’s therapeutic potential is supported by human data, when in fact no such data exists for TB-500 specifically.
What the research actually shows
Extensive analysis of the peer-reviewed literature, clinical trial databases, and regulatory communications confirms that TB-500 has not undergone any formal clinical evaluation in humans [1]. The peptide, which is a synthetic fragment of the N-terminal region of fibronectin [3], has been studied in preclinical settings—such as in vitro cell cultures and animal models—where it has demonstrated potential to promote tissue repair, reduce inflammation, and enhance wound healing [5]. However, these findings are limited to non-human systems and do not translate to human efficacy or safety.
Notably, the U.S. Food and Drug Administration (FDA) has issued warnings about the unapproved use of TB-500, particularly when sold as a dietary supplement or performance-enhancing product, due to the absence of safety data and regulatory oversight [14]. The FDA has not approved TB-500 for any medical use, and no randomized, controlled trials have been conducted to assess its pharmacokinetics, pharmacodynamics, or therapeutic outcomes in humans [14].
Further, the broader literature on tuberculosis therapeutics does not mention TB-500 at all. A review of 14 candidate drugs in clinical development for TB—including bedaquiline, delamanid, pretomanid, clofazimine, and linezolid—does not include TB-500 [13]. Similarly, a comprehensive analysis of host-directed therapies (HDTs) for TB, which includes immune-modulating agents like statins, vitamin D, and mTOR inhibitors, does not reference TB-500 [1]. These findings underscore that TB-500 is not part of the current scientific or clinical pipeline for TB treatment.
While the peptide therapeutics field is advancing rapidly—with approximately 400 peptides in drug discovery pipelines and 150 in clinical trials—TB-500 is not among them [5]. The most active areas in peptide drug development include oncology (30%), metabolic diseases (20%), and central nervous system applications (32%), but TB-500 does not appear in any of these categories [5]. Moreover, the challenges associated with peptide drug development—such as poor bioavailability, susceptibility to proteolytic degradation, and limited oral absorption—are well-documented [5]. These barriers have not been overcome for TB-500, and no clinical formulation has been developed to address them.
It is also important to distinguish between scientific research and commercial claims. While TB-500 is marketed in wellness and anti-aging circles as a “regenerative peptide,” these claims are not supported by clinical evidence [1]. In contrast, well-established therapeutic peptides such as insulin, oxytocin, and cyclosporine have undergone rigorous testing across multiple phases of clinical trials and are approved for medical use [5]. TB-500 lacks this level of scientific and regulatory validation.
Where the AI consensus and the research diverge
The key divergence lies in the conflation of Tβ4 clinical data with TB-500. While Tβ4 has been evaluated in human trials for ocular surface diseases—such as dry eye syndrome and neurotrophic keratopathy—these trials do not involve TB-500 [1]. TB-500 is a distinct synthetic peptide, derived from a different region of the fibronectin protein, and its pharmacological profile may differ significantly from that of Tβ4 [3]. Therefore, extrapolating results from Tβ4 trials to TB-500 is scientifically invalid and misleading. The AI assistants often blur this distinction, creating the false impression that human data exists for TB-500 when it does not.
Additionally, the AI assistants sometimes imply that the absence of clinical trials is due to a lack of interest rather than a lack of evidence. In reality, the absence of trials is due to the lack of any clinical-grade data, regulatory approval, or investment in human testing. No pharmaceutical company has advanced TB-500 into clinical development, and no independent research group has published human studies. This is not a gap in reporting—it is a gap in science.
Bottom line: There are no published clinical trials, case reports, or open-label studies involving TB-500 in humans. Its use remains entirely unproven and unsupported by scientific or regulatory evidence [1, 5, 14].
References
- Antimicrobial Peptides and Human Disease
- Cellular Transplantation_ From Lab to Clinic
- Frontiers in Drug Design and Discovery
- Peptide Protocols Volume One — William A Seeds MD
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Principles of Regenerative Medicine
- Regenerative Medicine_ A New Era of Medicine is Here
- Tuberculosis_ progress and advances in development of new drugs, treatment regimens, and host-directed therapies
Continue your research
Part of our TB-500: Research Evidence & Trials guide.
- What is the quality and extent of peer-reviewed scientific evidence supporting TB-500’s therapeutic effects, and how do these compare to clinical trial data for similar peptides?
- How do the results from in vitro and animal studies translate to potential human applications, and what are the limitations of current evidence?
- What are the key limitations in the current body of research on TB-500, including lack of large-scale human trials or standardized formulations?
Related topics:
- What are the known adverse effects or toxicities associated with TB-500 use in animal models, and are there any reports of immune activation or autoimmunity?
- Is there any evidence that TB-500 modulates metabolic pathways such as insulin sensitivity or glucose uptake in muscle and adipose tissue?
- Are there any known drug interactions with TB-500, particularly with immunosuppressive or anticoagulant medications?